Autopsy report · NCT04203901

Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

“Strategic corporate decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 3 years 2 months before it stopped.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

CoImmune

Sponsor type

Industry

Conditions

Advanced Renal Cell Carcinoma

Interventions

CMN-001; Nivolumab+Ipilimumab; Lenvatinib+Everolimus

Participants

16

Sites

9

Countries

United States

Trials that died the same way

• A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
  “Company's strategic decision” (94% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (91% match in meaning)
• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (91% match in meaning)
• CD8 Minibody Repeatability Study
  “Strategic decision” (90% match in meaning)
• A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
  “Corporate decision” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.